Moleculin Biotech is trading 21.6% down at $0.80 today, extending a sharp multi-day slide. - The company announced the pricing of a $9.3 million public offering at $0.75 per share, a significant discount to recent trading levels. - This offering, consisting of 12,376,667 shares and warrants, likely contributed to the decline, overriding the recent release of positive interim data from its pivotal MIRACLE AML trial.